Incretin mimetics are ideal candidate therapies for T2D as they exert their actions specifically during hyperglycaemic conditions and have the additional capacity to regulate body weight ( Since 2005, six incretin therapy drugs have been approved by the FDA (United States) and the MHRA (United Kingdom) for T2D treatment: Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Semaglutide and Tirzepatide, all of which are administered daily or once weekly via subcutaneous injection
Once a vial has been opened or punctured, it is commonly discarded within 1 Year , unless the manufacturers label provides different instructions
For the electron flow assays, mitochondria were plated in MAS buffer with 10 mM pyruvate + 2 mM malate + 4 M FCCP followed by 20 M rotenone in port A, 100 mM succinate in port B, 40 M antimycin A in port C and 1 mM TMPD + 100 mM ascorbic acid in port D
doi: 10.2174/1570161114666161221115324 43 ScheenAJ